Elicio Therapeutics Inc. stock dropped approximately 72.53% to $4.08 on June 15, 2026, after its Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) failed to meet its pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population. The decline pushed the stock to a new 52-week low and wiped out significant investor value just days after the company reported Q1 2026 financial results. Following the disclosure, law firm SueWallSt initiated an investigation into whether Elicio Therapeutics made materially false or misleading statements regarding the prospects of ELI-002 7P and the AMPLIFY-7P clinical program.

Financial Context and Analyst Ratings

On June 9, the company reported Q1 2026 earnings showing zero product revenue and a widening net loss driven by increased research and development expenses tied to the AMPLIFY-7P program. The company's cash position was stated to fund planned operations into the fourth quarter of 2026. Days before the trial data became public, B. Riley Securities had issued a Buy rating with a $27 price target on June 10-11. The stock closed at only $4.08 after the Phase 2 miss was disclosed on June 15, resulting in substantial losses for investors who purchased shares at higher prices.

Key Findings and Analysis

The randomized study evaluated ELI-002 7P as an adjuvant treatment. While the primary endpoint was not met, landmark analyses during active treatment showed an approximately 14% absolute improvement in DFS at both three and six months compared with observation. Treatment-arm separation emerged during active therapy and continued through nine months. Randomization balanced most prognostic factors, but the ELI-002 7P arm had a higher proportion of R1 resected patients compared with the observation arm (ELI-002 7P 19% vs. observation 10%). R1 resection is a known adverse prognostic factor for recurrence.

Biological Activity and Safety

Post-hoc analysis identified a stronger DFS hazard ratio in the R0, completely resected population, indicating potential for a significant population with high unmet need. This subgroup represented roughly 84% of enrolled patients. The data demonstrated a hazard ratio of 0.65 with a p-value of 0.048. The median DFS was 23.8 months for the ELI-002 7P arm compared to 12.8 months for the observation arm in this subgroup. Absolute recurrence rates observed at 18 months were 9.5% lower for the ELI-002 7P arm. Mutant KRAS (mKRAS)-specific T cell responses strongly correlated with improved DFS, supporting the biological activity of ELI-002 7P. The analysis showed a hazard ratio of 0.22 with a p-value of less than 0.0001. ELI-002 7P demonstrated a favorable safety profile, with no treatment-related discontinuations or deaths reported.

Future Development Strategy

The findings inform a refined Phase 3 development strategy focused on a defined R0 resected population and additional ELI-002 7P dosing. The proposed registrational study is expected to use disease-free survival as its primary endpoint and include additional dosing beyond the current immunization and booster regimen. Investors who purchased Elicio Therapeutics shares and suffered a loss are encouraged to contact Joseph E. Levi, Esq. to discuss their legal rights.

Jones Trading analyst Boris Peaker has downgraded Elicio Therapeutics from Buy to Hold. The revised rating signals a change in the investment firm's outlook regarding the company's stock performance.

Rating Change Details

The adjustment moves Elicio Therapeutics out of a Buy recommendation, suggesting that the previous potential for significant upside may have diminished. The downgrade applies to the company's shares listed on NASDAQ under the ticker ELTX.

The Hold rating indicates that investors are advised to maintain their current positions rather than accumulate additional shares, based on the analyst's assessment.